NASDAQ
RxSight, Inc. (RXST)
♥ 610 Thanks from members
RxSight, Inc. (RXST) faces a strategic pivot in Q2 2026, featuring a 19% decline in core product sales and withdrawn full-year guidance under new CEO Aziz Mottiwala, countered by a lucrative Alcon collaboration and strong $209M cash reserves.